Hyperbaric Oxygen Therapy and Aging: The Pressure Chamber Fountain of Youth

A Pressurized Tube, a Viral Study, and the Biohacker Gold Rush

Somewhere around late 2020, a study from Tel Aviv University broke the internet — or at least the corner of it that tracks longevity research. The headline was irresistible: hyperbaric oxygen therapy had lengthened telomeres and cleared senescent cells in a group of older adults. In the language of aging biology, that is roughly equivalent to claiming you found a way to rewind the clock.

The biohacking community responded predictably. Podcast hosts breathlessly covered the findings. Wellness clinics added HBOT to their menus alongside IV drips and cryotherapy. Home chamber manufacturers saw sales spike. And a new commercial clinic chain — founded by the lead researcher himself — opened luxury locations in Florida and Dubai, offering 60-session anti-aging protocols to anyone willing to pay.¹

Five years later, the evidence picture is more complicated than the headlines ever suggested. I've spent weeks working through the full clinical literature on HBOT and aging, and what I found is a familiar pattern: promising mechanistic data, enthusiastic marketing, and a crucial RCT that almost nobody mentions — because it failed.

What Hyperbaric Oxygen Actually Does to Your Body

The basic premise of HBOT is simple. You sit or lie inside a sealed chamber while the pressure is raised to 1.5–2.4 times normal atmospheric pressure (measured in atmospheres absolute, or ATA), breathing 100% oxygen. Under these conditions, your blood plasma dissolves 10 to 15 times more oxygen than it normally carries.² That oxygen-saturated blood reaches tissues that might otherwise be starved — damaged wounds, compromised grafts, tissues suffocating under swelling.

This is not fringe medicine. HBOT has been used clinically since the 1960s, and the Undersea and Hyperbaric Medical Society (UHMS) recognizes 14 FDA-approved indications, including decompression sickness, carbon monoxide poisoning, gas gangrene, crush injuries, and — most significantly for its evidence base — diabetic foot ulcers.³ For chronic non-healing wounds, the data is robust: a Medicare coverage analysis found that 46% of HBOT-treated diabetic ulcers healed completely versus 23% with standard care alone.⁴

The anti-aging hypothesis extends this logic. Proponents argue that repeated cycles of hyperoxia (high oxygen) and normoxia (normal oxygen) — essentially pressurizing and depressurizing the body across 40 to 60 sessions — trigger a cascade of beneficial responses: stem cell mobilization, angiogenesis (new blood vessel growth), reduced inflammation, and activation of cellular repair pathways.⁵ The mechanism is sometimes compared to exercise — controlled stress that forces adaptation. It's a reasonable biological hypothesis. The question is whether the human data supports it.

35 People, 60 Sessions, and the Headlines That Launched an Industry

The study that started the anti-aging HBOT movement was published in November 2020 in the journal Aging by Hadanny, Efrati, and colleagues at the Sagol Center for Hyperbaric Medicine and Research in Israel. It enrolled 35 healthy adults aged 64 and older in a protocol of 60 daily HBOT sessions at 2.0 ATA, each lasting 90 minutes with intermittent air breaks.¹

The results, on paper, were remarkable. Telomere length — a widely discussed biomarker of cellular aging — increased by 20 to 37% across different immune cell populations. B-cell telomeres showed the most dramatic change at +37.6%. Meanwhile, senescent T-helper cells (the "zombie cells" that accumulate with age and drive chronic inflammation) decreased by 37.3%.¹

I want to be clear about what this study did and did not show. It demonstrated that a specific HBOT protocol changed certain biomarkers in blood cells over a 3-month period. It did not demonstrate that those changes translated into any measurable health benefit — no improvement in cognition, physical function, disease risk, or lifespan was reported. It did not include a control group, which means we cannot rule out that the act of visiting a clinic 60 times, receiving medical attention, and maintaining a structured routine contributed to the observed changes. And critically, the follow-up stopped just 1–2 weeks after the last session.¹

There is also a deeper concern that rarely surfaces in the coverage. Senescent cells — the "zombies" this treatment is meant to clear — accumulate for a reason. They serve as a brake on damaged cells that might otherwise proliferate. Artificially extending telomeres while suppressing senescence markers could theoretically increase cancer risk, by allowing cells that should have stopped dividing to keep going. This is not a hypothetical concern — it is a recognized tension in the aging biology literature. The Hadanny study did not assess cancer biomarkers or long-term malignancy risk.⁶

A companion study from the same group examined skin biopsies from 13 participants in a related protocol and found increased collagen density, elastic fiber length, and blood vessel density — encouraging histological findings, but from a cohort so small that it barely qualifies as preliminary.⁷

154 Patients, a Proper RCT, and the Result Nobody Wanted

Here is where the narrative fractures. In 2025, BenAri, Efrati, Hadanny, and colleagues published the results of the largest and most rigorous HBOT aging-related trial to date — a double-blind, sham-controlled randomized controlled trial enrolling 154 older adults with mild cognitive impairment (MCI) and type 2 diabetes.⁸

This was exactly the kind of trial the field needed: proper randomization, a sham control group (participants sat in a chamber with minimal pressure change), blinding, and a large enough sample to detect meaningful effects. The protocol ran approximately 60 sessions.

The result: HBOT did not improve cognitive outcomes versus sham. Brain imaging showed no significant differences. And the safety data raised a red flag that deserves more attention than it has received — the HBOT group experienced three times as many serious adverse events as the sham group (25 vs. 8).⁸

This trial does not erase the telomere findings — they measured different things in different populations. But it severely undermines the broader narrative that HBOT "reverses aging" in any clinically meaningful way. When you move from open-label biomarker studies to a properly controlled trial measuring actual health outcomes, the magic disappears.

It's worth noting that the research group's one clearly positive RCT was in post-COVID patients — a 73-person trial published in Scientific Reports in 2022 that showed moderate improvements in cognition, energy, and psychiatric symptoms versus sham.⁹ That is a legitimate finding. But post-COVID cognitive dysfunction is a distinct clinical entity from age-related cognitive decline, and extrapolating from one to the other is exactly the kind of leap that keeps getting this field in trouble.

When the Researcher Also Sells the Treatment

I try not to let conflicts of interest override data. Researchers need funding, and industry collaboration is not inherently corrupting. But the HBOT aging field has a conflict structure that demands disclosure.

Shai Efrati is the director of the Sagol Center for Hyperbaric Medicine and Research — the lab that has produced virtually every human study on HBOT and aging. He is also a co-founder of Aviv Scientific, a commercial HBOT clinic chain with premium locations in Florida and Dubai that markets anti-aging protocols directly to consumers.¹⁰ His colleague Amir Hadanny, lead author on most of the key papers, also works for Aviv Scientific.

To their credit, these affiliations are disclosed in the publications. The science is not fabricated. But the structure is unmistakable: the same team that produces the research also profits commercially when that research generates positive headlines. There are no independent research groups anywhere in the world that have replicated the telomere or senescent cell findings. Five years after the 2020 study, the entire anti-aging HBOT evidence base rests on the output of a single lab with direct financial ties to the industry.

This is not a reason to dismiss the data outright. But it is a reason to demand independent replication before accepting the conclusions — and that replication simply does not exist yet.

$250 Per Session, 60 Sessions, and a Home Chamber in Your Garage

The economics of HBOT for anti-aging are straightforward and eye-watering. A clinical session at a hospital or specialized center runs $250 to $600, depending on location and facility type. The standard anti-aging protocol involves 40 to 60 sessions, putting the total cost at roughly $10,000 to $36,000 — and insurance does not cover HBOT for anti-aging under any circumstances.¹¹ Medicare and most private insurers restrict coverage to the 14 FDA-approved indications, primarily wound care and decompression sickness.

The home chamber market has exploded in response. But there is a critical distinction that rarely makes it into the marketing material. Medical-grade hard-shell chambers operate at 2.0–2.4 ATA with 100% oxygen — this is what was used in every study I've cited. Consumer soft-shell (mild) chambers operate at only 1.3–1.4 ATA with ambient or concentrated air, not pure oxygen. They cost $4,000 to $15,000 and are marketed aggressively as home wellness devices.¹²

The UHMS — the same organization that maintains the evidence-based list of approved HBOT indications — has issued a formal position statement declaring that pressures below 1.4 ATA have "no reliable clinical evidence" supporting their use.¹² In other words, the studies showing biomarker changes used medical-grade chambers at 2.0 ATA, while the devices most consumers can actually buy operate at a pressure the scientific community considers clinically meaningless.

The FDA has repeatedly warned consumers about unapproved HBOT devices and clinics making medical claims without evidence, noting that HBOT is only approved for specific conditions and that off-label promotion is potentially dangerous.¹³ None of this has slowed the market.

Pressurized Oxygen Is Real Medicine — Just Not for What They're Selling

Here is what I can say with confidence: HBOT is a legitimate medical therapy with strong evidence for specific conditions, particularly chronic non-healing wounds. The mechanism by which repeated hyperoxia-normoxia cycles could influence cellular aging is biologically plausible and worth studying. The biomarker data from the 2020 telomere study is genuinely interesting, even if it comes from a small, uncontrolled trial with significant conflicts of interest.

And here is what I cannot say: that HBOT "reverses aging." That it makes your cells younger. That it extends lifespan or prevents age-related disease. The largest, best-designed RCT examining HBOT for cognitive aging was negative — no benefit over sham, with more side effects. The telomere findings have not been replicated by a single independent lab in five years. The skin biopsy data comes from 13 people. And the commercial clinics charging five figures for anti-aging protocols are operating on enthusiasm, not evidence.